Clinical Trials Logo

Heart Failure With Preserved Ejection Fraction clinical trials

View clinical trials related to Heart Failure With Preserved Ejection Fraction.

Filter by:

NCT ID: NCT03619213 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

DELIVER
Start date: August 27, 2018
Phase: Phase 3
Study type: Interventional

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

NCT ID: NCT03617848 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Optimising Management of Patients With Heart Failure With Preserved Ejection Fraction in Primary Care

OPTIMISEHFpEF
Start date: July 17, 2018
Phase:
Study type: Observational

Heart failure (HF) accounts for 2% of National Health Service (NHS) expenditure, and 5% of emergency hospitalisations. Patients with HF with preserved ejection fraction (HFpEF) are older, have more comorbidities, have similarly poor or worse outcomes compared to patients with reduced ejection fraction (HFrEF), and currently lack an evidence base for treatment. The investigators hypothesise that outcomes of patients with HFpEF can be improved through optimised management and self-management of comorbidities, fluid status and lifestyle delivered in primary care in collaboration with specialists. The primary aim is to develop a programme of optimised management by improving understanding of needs and experiences of patients with HFpEF, clinical decision-making and management in primary care, and integrating research findings with patient and clinical expertise. The main objective for this work package is to identify patients with HFpEF in primary care and assess comorbidities and other factors, management, morbidity and mortality at one year. The methodology employed will be a longitudinal cohort study of 270 patients with HFpEF in primary care followed for 12 months.

NCT ID: NCT03550235 Not yet recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)

NEON HFpEF
Start date: June 2018
Phase:
Study type: Observational

Patients with unexplained stress dyspnea ( ≥ stage 2 NYHA), no significant underlying lung disease, with an ejection fraction > 50%, normal resting filling pressures, NTproBNP < 220 pg/ml in < 75 years, and < 450 pg/ml in ≥ 75 years will be studied with stress echocardiography and cardiometabolic stress test (VO2). These patients may have abnormal adaptation during exercise, suggesting that chronic symptoms may be related to a heart failure with preserved ejection fraction (HFPEF). More accurate and earlier diagnosis of HFPEF using stress echocardiography and VO2 may better manage stress dyspnea in patients and prevent progression of HFPEF. A clinical assessment will be offered to people with unexplained stress dyspnea. The procedures and products used in this study are usually used as part of HFpEF's diagnostic strategy. During this assessment, carried out on an outpatient basis, an anamnesis collection, a cardiovascular clinical examination, an evaluation of dyspnea by the NYHA functional class and by 2 questionnaires, an electrocardiogram will be carried out, a 6-minute walk test, a biological blood test, a trans thoracic rest and stress cardiac ultrasound, respiratory functional tests (with diffusion capacity of lung for carbon monoxide (DLCO) and blood gas), and a metabolic stress test. A follow-up at 1 and 2 years is planned (visit, sampling and resting echocardiography).

NCT ID: NCT03506412 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

CNEPi
Start date: June 25, 2018
Phase: Phase 4
Study type: Interventional

To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.

NCT ID: NCT03414632 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Transthyretin Cardiac Amyloidosis in HFpEF

Start date: December 1, 2017
Phase: Early Phase 1
Study type: Interventional

To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

NCT ID: NCT03351179 Enrolling by invitation - Clinical trials for Acute Myocardial Infarction

Predictors and Outcomes of In-hospital HFpEF in AMI Patients

Start date: January 1, 2013
Phase: N/A
Study type: Observational

This retrospective observation is to investigate the incidence,clinical outcomes and prognosis of hospitalized heart failure with preserved ejection fraction (HFpEF) in patients with acute myocardial infarction(AMI).

NCT ID: NCT03340233 Withdrawn - Healthy Clinical Trials

Understanding the Mechanisms of Diastolic Dysfunction

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Heart failure is a clinical syndrome marked by breathlessness, even at low levels of exertion, general fatigue, and fluid retention and is estimated to affect 5.1 million people in the United States. Heart failure with preserved ejection fraction (HFpEF) means that the heart pumps enough blood to the body, but patients still have terrible symptoms. It is estimated to account for about 50% of all heart failure cases. Experts agree that impaired filling of the heart, perhaps due to "stiffness" of the heart muscle itself, critically underlies HFpEF. There is currently no clinical technique for measuring heart muscle (myocardial) stiffness; the very definition of "myocardial stiffness" remains poorly established. Consequently, the ability to study the mechanisms that underlie HFpEF is virtually non-existent, and limited treatment options will persist without significant advances. The objective of this project is to use an Equilibrium-Material-Stability (EMS) framework that couples patient-specific clinical MRI and heart pressure data in a computational model of the heart to diagnose changes in myocardial stiffness. The central hypothesis is that the new EMS framework for understanding the mechanisms of diastolic dysfunction in HFpEF will be more sensitive and outperform currently available approaches.

NCT ID: NCT03254485 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

CAPACITY-HFpEF
Start date: November 7, 2017
Phase: Phase 2
Study type: Interventional

The objective of the CAPACITY-HFpEF study is to evaluate the safety and efficacy of IW-1973 compared with placebo when administered daily for approximately 12 weeks to patients with HFpEF. The study will evaluate the effect of oral IW-1973 on peak exercise capacity in patients with HFpEF, with or without permanent or persistent atrial fibrillation.

NCT ID: NCT03226652 Recruiting - Heart Failure Clinical Trials

Heart Function in Patients Assessed for Sleep Apnoea

Start date: July 24, 2017
Phase:
Study type: Observational

This study aims to determine the prevalence and prognosis of heart failure with preserved ejection function (HFpEF) among patients being assessed for sleep disordered breathing (SDB).

NCT ID: NCT03160625 Withdrawn - Clinical trials for Heart Failure With Preserved Ejection Fraction

Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF

RESPOND-HF
Start date: July 1, 2017
Phase: N/A
Study type: Interventional

RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with preserved ejection fraction, referred to as HFpEF patients. Findings from this pilot study may be used to guide subsequent efforts to design and conduct a prospective, randomized, multi-center pivotal trial powered to show improvement in patient outcomes.